IGC Pharma, Inc. Cash Flow Statement
IGC|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
IGC Pharma, Inc. used $5M in operating cash flow and negative free cash flow of $5M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$7.1M | -$11.5M | -$15.0M | -$8.8M | -$7.3M | -$4.1M | -$1.8M | -$1.9M | -$2.8M | -$4.6M | -$3.0M | -$2.3M | -$7.8M | -$7.8M | -$20.2M |
| Depreciation & Amortization | $618.0K | $657.0K | $651.0K | $478.0K | $144.0K | $59.0K | $19.0K | $396.3K | $728.7K | $781.5K | $712.3K | $673.9K | $996.4K | $996.4K | $785.1K |
| Operating Cash Flow | -$4.8M | -$7.0M | -$7.5M | -$10.8M | -$8.7M | -$3.3M | -$1.9M | -$1.4M | -$157.7K | -$2.6M | -$1.7M | $564.8K | -$5.0M | -$5.0M | -$2.6M |
| Capital Expenditures | $112.0K | $310.0K | $236.0K | $1.5M | $4.4M | $15.0K | $136.0K | $145.7K | $122.2K | $76.5K | $8.5K | $326.1K | $5.5K | $5.5K | $285.4K |
| Free Cash Flow | -$4.9M | -$7.4M | -$7.7M | -$12.3M | -$13.1M | -$3.3M | -$2.1M | -$1.5M | -$279.9K | -$2.7M | -$1.8M | $238.8K | -$5.0M | -$5.0M | -$2.9M |
| FCF Margin | -386.1% | -807.6% | -1939.0% | -1366.4% | -320.9% | -65.4% | -94.3% | -264.8% | -4.4% | -34.6% | -77.0% | 3.0% | -119.7% | -119.7% | -71.7% |